| Literature DB >> 28058180 |
Koichi Oishi1, Hirofumi Noguchi2, Hiroaki Saito3, Hiroshi Yukawa1, Yoshitaka Miyamoto1, Kenji Ono4, Katsutoshi Murase3, Makoto Sawada4, Shuji Hayashi1.
Abstract
Significant graft loss immediately after islet transplantation occurs due to immunological and nonimmunological events. Magnetic resonance imaging (MRI) is an attractive potential tool for monitoring islet mass in vivo. Although an efficient uptake of MRI contrast agent is required for islet cell labeling, commercially available magnetic nanoparticles are not efficiently transduced into cells. In this study, we developed six kinds of novel magnetic iron oxide nanoparticles, which are electrically charged by cationic end-group substitution of dextran. Each of the nanoparticles consisted of a small monocrystalline, superparamagnetic iron oxide core that is stabilized by a cross-linked aminated dextran coating to improve stability. We also used three different commercially available nanoparticles for controls. The labeling efficiency of the novel nanoparticles was evaluated, and the feasibility of the imaging by MRI was assessed. The positive-charged nanoparticles were transduced into a β-cell line, MIN6 cells, but not three commercially available nanoparticles. MRI showed a marked decrease in signal intensity on T1- and T2-weighted images at the site of the labeled cells in vitro. These data suggest that novel positive-charged nanoparticles could be useful MRI contrast agents to monitor islet mass after transplantation.Entities:
Keywords: Cationic nanoparticles; Dextran; In vivo imaging; Islet transplantation; Magnetic resonance imaging (MRI)
Year: 2012 PMID: 28058180 PMCID: PMC5196926 DOI: 10.3727/215517912X639397
Source DB: PubMed Journal: Cell Med ISSN: 2155-1790